Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.

Author:

Brose Marcia S.1,Nutting Christopher2,Jarzab Barbara3,Elisei Rossella4,Siena Salvatore5,Bastholt Lars6,de la Fouchardiere Christelle7,Pacini Furio8,Paschke Ralf9,Shong Young Kee10,Sherman Steven I.11,Smit Johannes WA12,Chung John Woojune13,Siedentop Harald14,Molnar Istvan13,Schlumberger Martin15

Affiliation:

1. Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

2. The Royal Marsden NHS Foundation Trust, London, United Kingdom

3. Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

4. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

5. Azienda Ospedaleria Niguarda Ca' Granda, Milano, Italy

6. Odense University Hospital, Odense, Denmark

7. Consortium Cancer Thyroïdien, Hospices Civils-Centre Anticancéreux, Lyon, France

8. Unit of Endocrinology, University of Siena, Siena, Italy

9. Department for Endocrinology and Nephrology, Leipzig University, Leipzig, Germany

10. Asan Medicine Center, University of Ulsan College of Medicine, Seoul, South Korea

11. The University of Texas MD Anderson Cancer Center, Houston, TX

12. Department of Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

13. Bayer HealthCare Pharmaceuticals, Montville, NJ

14. Bayer Pharma AG, Berlin, Germany

15. Institut Gustave Roussy, Villejuif, France

Abstract

4 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3